Remove laetitia.bachelot-fontaine@valneva.com�
article thumbnail

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Pfizer

VLA15 has demonstrated a strong immune response and satisfactory safety profile in pre-clinical and clinical studies so far. Pfizer Disclosure Notice The information contained in this release is as of February 17, 2023. VP Global Investor Relations M +1 917 815 4520 joshua.drumm@valneva.com References 1. Pfizer.